Radiopharm Theranostics Files 6-K Report

Ticker: RDPTF · Form: 6-K · Filed: Oct 20, 2025 · CIK: 1949257

Radiopharm Theranostics Ltd 6-K Filing Summary
FieldDetail
CompanyRadiopharm Theranostics Ltd (RDPTF)
Form Type6-K
Filed DateOct 20, 2025
Risk Levellow
Pages1
Reading Time1 min
Key Dollar Amounts$35 M, $5 M
Sentimentneutral

Sentiment: neutral

Topics: 6-K, foreign-private-issuer, regulatory-filing

TL;DR

Radiopharm Theranostics (RPT) filed a 6-K, confirming 20-F annual report filing and Aussie HQ.

AI Summary

Radiopharm Theranostics Ltd, a pharmaceutical preparations company, filed a Form 6-K on October 20, 2025. The filing is a report of a foreign private issuer and indicates the company will file annual reports under Form 20-F. The company's principal executive office is located in Carlton South, Victoria, Australia.

Why It Matters

This filing provides an update on Radiopharm Theranostics' status as a foreign private issuer, which is relevant for investors tracking its regulatory compliance and reporting obligations in the US.

Risk Assessment

Risk Level: low — This is a routine filing for a foreign private issuer and does not contain new financial or operational information that would typically increase risk.

Key Numbers

  • 001-41621 — SEC File Number (Identifies the company's filing history with the SEC.)

Key Players & Entities

  • Radiopharm Theranostics Ltd (company) — Registrant
  • 001-41621 (company) — SEC File Number
  • October 2025 (date) — Reporting Period
  • Carlton South, Victoria, Australia (location) — Principal Executive Office

FAQ

What type of filing is this Form 6-K?

This Form 6-K is a Report of Foreign Private Issuer.

Which annual report form does Radiopharm Theranostics indicate it will file?

Radiopharm Theranostics indicates it will file annual reports under cover of Form 20-F.

Where is Radiopharm Theranostics' principal executive office located?

The principal executive office is located at Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia.

What is the Commission File Number for Radiopharm Theranostics?

The Commission File Number for Radiopharm Theranostics is 001-41621.

Does Radiopharm Theranostics furnish information under Rule 12g3-2(b)?

No, the registrant indicates it is not furnishing information to the Commission pursuant to Rule 12g3-2(b).

Filing Stats: 357 words · 1 min read · ~1 pages · Grade level 18.1 · Accepted 2025-10-20 06:46:19

Key Financial Figures

  • $35 M — 0, 2025 titled: “RAD completes A$35 M Placement and launches A$5 M SPP”
  • $5 M — ompletes A$35 M Placement and launches A$5 M SPP” “RAD Provides Positi

Filing Documents

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission File Number: 001-41621 RADIOPHARM THERANOSTICS LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- RADIOPHARM THERANOSTICS LIMITED EXPLANATORY NOTE Radiopharm Theranostics Limited (the “Company”) published three announcements (the “Public Notice”) to the Australian Securities Exchange on October 20, 2025 titled: “RAD completes A$35 M Placement and launches A$5 M SPP” “RAD Provides Positive Clinical Updates Across Four Programs” “Investor Presentation - Clinical Update and Capital Raising” A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 RAD completes A$35 M Placement and launches A$5 M SPP 99.2 RAD Provides Positive Clinical Updates Across Four Programs 99.3 Investor Presentation - Clinical Update and Capital Raising 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. RADIOPHARM THERANOSTICS LIMITED Date: October 20, 2025 By: /s/ Phillip Hains Phillip Hains Company Secretary 3

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.